| |
Join us on Dec. 7 for a webinar exploring compendia surveillance and Eurofins BioPharma Product Testing’s processes in maintaining compliance. Register now.
|
|
Today’s Big NewsNov 8, 2023 |
|
January 9-10, 2024 | San Francisco, CA
January 16-18, 2024 | Virtual
Scoring for Patients: How Reducing Risk in 2023 Will Change the Fame for Drug Discovery and Development
Register today and Save $450!
|
|
| By Kevin Dunleavy In the big pharma battle to treat obesity, Novo Nordisk sprinted to an early lead but Eli Lilly is catching up quickly. |
|
|
|
By James Waldron Lumos Pharma's stock jumped this morning as a successful phase 2 trial maintained the Texan biotech’s hopes of bringing the first oral drug for pediatric growth hormone deficiency to market. |
By Conor Hale Recor Medical's renal denervation approach tackles high blood pressure that hasn’t responded to medications or changes in lifestyle. |
By Kevin Dunleavy In three years as the pharma chief at Roche, Bill Anderson executed a massive overhaul of the division, lopping off layers of management and recharting its course. Now in his fifth month as CEO at struggling conglomerate Bayer, Anderson is focused on an even larger renovation, saying the company is on its way to a “radical realignment” with massive reductions in its workforce. As part of the realignment, Bayer also is evaluating separating its consumer health and crop science divisions. |
By Nick Paul Taylor Xencor and CytomX Therapeutics have taken a scalpel to their pipelines, stopping work on an ex-AbbVie antibody-drug conjugate and pulling back from a co-development deal with Genentech to focus cash on other projects. |
By Andrea Park Helping toddlers manage their Type 1 diabetes—typically a difficult task, due to their constant growth and development—may now be a bit easier. |
By Fraiser Kansteiner While Biogen CEO Chris Viehbacher seems satisfied with the company's third-quarter financial metrics, the main question at the drugmaker isn’t so much how the company’s doing now, but what its plans are for future growth, he said on a call with investors. |
By James Waldron A year after Lyell Immunopharma lost a $1 billion biobucks partnership with GSK, the cell therapy biotech is offloading a quarter of its staff and deprioritizing some earlier-stage research to extend funding into 2027. |
By Zoey Becker The company attributes the gradual pace of CAR-T uptake to the "fragmentation" of the U.S. healthcare system, Kite head Cindy Perettie said on an earnings call. Together, Kite's Yescarta and Tecartus posted third-quarter sales of $487 million. |
By Andrea Park More than a decade into their partnership, Masimo and GE HealthCare are still finding new ways to combine their respective patient monitoring technologies. |
Fierce podcastsDon’t miss an episode |
| | Hello Heart is a U.S.-based company with offices in California and New York, and it also has a significant presence in Israel, with the majority of its roughly 80 employees there working from the Tel Aviv office. In this week’s episode of “Podnosis,” Hello Heart CEO Maayan Cohen, who resides in Tel Aviv, shares her personal experience during a challenging moment when she was on her way to the annual HLTH conference in Las Vegas and heard about the October 7th attack by Hamas on Israel. |
|
|---|
|
|
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
